367 related articles for article (PubMed ID: 18070940)
21. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of atorvastatin after LDL-cholesterol-based dose selection in high risk dyslipidaemic patients: results of the target dose study.
Ducobu J; Claeys M; Commers K; Van Mieghem W; Nachtergaele H; Vandenbroucke M; Deforce J
Curr Med Res Opin; 2007 Aug; 23(8):1821-7. PubMed ID: 17609019
[TBL] [Abstract][Full Text] [Related]
23. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
[TBL] [Abstract][Full Text] [Related]
24. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
Rouleau J
Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
[TBL] [Abstract][Full Text] [Related]
26. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.
Pitt B; Waters D; Brown WV; van Boven AJ; Schwartz L; Title LM; Eisenberg D; Shurzinske L; McCormick LS
N Engl J Med; 1999 Jul; 341(2):70-6. PubMed ID: 10395630
[TBL] [Abstract][Full Text] [Related]
27. Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE).
Deedwania PC;
Am Heart J; 2004 Dec; 148(6):1053-9. PubMed ID: 15632893
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
[TBL] [Abstract][Full Text] [Related]
29. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
[TBL] [Abstract][Full Text] [Related]
30. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk.
Boh M; Opolski G; Poredos P; Ceska R; Jezovnik M
Int Angiol; 2011 Aug; 30(4):366-74. PubMed ID: 21747355
[TBL] [Abstract][Full Text] [Related]
32. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk.
Blanco-Colio LM; Martín-Ventura JL; Gómez-Guerrero C; Masramon X; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Egido J
Eur J Pharmacol; 2008 May; 586(1-3):259-65. PubMed ID: 18374327
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
34. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
Hague W; Forder P; Simes J; Hunt D; Tonkin A;
Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
[TBL] [Abstract][Full Text] [Related]
35. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
[TBL] [Abstract][Full Text] [Related]
36. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
Roeters van Lennep HW; Liem AH; Dunselman PH; Dallinga-Thie GM; Zwinderman AH; Jukema JW
Curr Med Res Opin; 2008 Mar; 24(3):685-94. PubMed ID: 18226326
[TBL] [Abstract][Full Text] [Related]
37. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months: a multicenter, randomized, double-blind trial.
Schmermund A; Achenbach S; Budde T; Buziashvili Y; Förster A; Friedrich G; Henein M; Kerkhoff G; Knollmann F; Kukharchuk V; Lahiri A; Leischik R; Moshage W; Schartl M; Siffert W; Steinhagen-Thiessen E; Sinitsyn V; Vogt A; Wiedeking B; Erbel R
Circulation; 2006 Jan; 113(3):427-37. PubMed ID: 16415377
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease.
Conard SE; Bays HE; Leiter LA; Bird SR; Rubino J; Lowe RS; Tomassini JE; Tershakovec AM
Am J Cardiol; 2008 Dec; 102(11):1489-94. PubMed ID: 19026302
[TBL] [Abstract][Full Text] [Related]
39. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
Nissen SE
Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
[TBL] [Abstract][Full Text] [Related]
40. Effects of Atorvastatin on LDL sub-fractions and peroxidation in type 1 diabetic patients: a randomised double-blind placebo-controlled study.
Manuel-Y-Keenoy B; Van Campenhout C; Vertommen J; De Leeuw I
Diabetes Metab Res Rev; 2003; 19(6):478-86. PubMed ID: 14648807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
